LYNPARZA (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Apr 29, 2019--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medici…
